COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial
Status:
Completed
Trial end date:
2021-06-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, dose-requirements, and exploratory
efficacy of twice-daily subcutaneous enoxaparin as venous thromboembolism prophylaxis in
children (birth to 18 years) hospitalized with signs and/or symptoms of SARS-CoV-2 infection
(i.e., COVID-19).
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins All Children's Hospital Neil Goldenberg